The most promising targets in the advanced stage of clinical development include GPRC5D and FcRH5, which demonstrate high specificity to myeloma cells, the favorable safety profile, and efficacy in patients who had earlier received BCMA-specific therapy. This evidence concerns the gene GPRC5D and plasma cell myeloma.